.png "Charles River Labs (NYSE: CRL)")
After RBC Capital and Jefferies gave Charles River Labs (NYSE: CRL) a Buy rating last month, the company received another Buy, this time from Robert W. Baird. Analyst Eric Coldwell reiterated a Buy rating on Charles River Labs yesterday and set a price target of $133. The company’s shares closed yesterday at $124.18.
According to TipRanks.com, Coldwell is a 4-star analyst with an average return of 6.9% and a 53.7% success rate. Coldwell covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Walgreens Boots Alliance, and Quest Diagnostics Inc.
Charles River Labs has an analyst consensus of Strong Buy, with a price target consensus of $133.50.
See today’s analyst top recommended stocks >>
Based on Charles River Labs’ latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $52.63 million. In comparison, last year the company had a net profit of $53.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions.
